Check out our latest video; What can the app do for you?
We want to make sure that all of our users are able to get the most out of their Breathe RM app. Let us guide you through the app and show you how to make the most of the features.
You asked, we built it: blood glucose tracking
If you use a continuous glucose monitor (CGM) you may have heard about ‘Time in Range’, sometimes called Time in Target. This is usually shown in your CGM app or reader as a percentage. It tells you how much time in the last 24 hours your blood glucose was in range. This range is often set between 4-9 mmol/L but you or your diabetes team may have tailored this to you. We wanted to add a metric that would help users understand the relationship between lung function and blood glucose over time. Now you can find out if an exacerbation affected your blood glucose or if tighter glucose control has a link to your lung function. Best of all, you can add TiR for past dates, by scrolling through the calendar function and adding your % on previous days.
To add your Time in Range, view your latest TiR number in your CGM settings (see here for how to do this if you’re using a Dexcom or a Libre) then on the Breathe home screen tap the tile marked ‘blood glucose’ and enter your data. Once you have entered a number you can view a TiR graph and overlay lung function (Fev1) by tapping the breathe icon in the bottom right corner. We hope this will be useful for community users who self-monitor with Breathe and for users who use the app with CF teams in clinic.
We are proud to have received Orcha certification in 2023, a great endorsement of our hard work and quality assurance in the digital health space
We are always listening
The Breathe team is here to help! We are never too busy to hear from our users and there are no silly questions. Need troubleshooting advice? Drop us an email, or use the in-app contact form.
Want to give us some feedback or tell us about an idea for a new feature? Tell us more in our 5 minute Breathe RM survey.
Making Breathe work for you.
We know CF is about more than lungs and that some users struggle with daily FEV1 input. We recently created four user styles designed to show all the different ways that Breathe RM can help you monitor symptoms and discover trends in your health. Read more in the article below≥.
These user styles were created with the feedback you gave us about using the app. We’d love to know which style you are? Tell us more in the Breathe Flex survey.
Thank you for helping us build Breathe RM & being part of our community.
Making Breathe RM work for you.
Thank you for helping us develop Breathe RM into what it is today. Because of your participation we have been able to improve the app in many ways. Royal Papworth hospital has recently secured more funding from the National Institute of Healthcare Research (NIHR) to advance the use of Breathe RM in CF and bronchiectasis (NCFB) . This would not have been possible without the data that all our users have captured through the app since 2019.
We know that users get more from Breathe RM, the more they use it. You have told us that many of you like to use the app in different ways. So we have created a guide to empower you to use Breathe RM in a way that is most useful to you and your own health goals.
We want you to use Breathe in a way that makes sense to you. The more data you enter, the more you and your CF team can learn in the long-term. However, we understand that certain metrics come with feelings attached. Some users told us that recording their lung function can make them anxious at times. We discuss some ways of managing that in the user styles below. Users shared different reasons for taking part in Project Breathe, ranging from motivation to keep fit, a passion for health research, reassurance they were stable before holidays or life events and even a desire to track complex parts of CF health.
Which of these user styles best represents you? Maybe you identify with more than one. Read on and let us know how you like to use Breathe via our new CareCircle chat room.
Disclaimer: Please be mindful that if you are taking part in the upcoming ACE CF trial, you may need to complete your spirometry more often.
*Press Release December 2022*
Royal Papworth Hospital awarded £3.4 million for major new UK-wide cystic fibrosis and bronchiectasis trials
Researchers at Royal Papworth Hospital NHS Foundation Trust will receive £3.4 million to fund new UK-wide trials investigating if machine-learning technology can transform how people living with chronic respiratory conditions manage their health.
Previous studies have shown it has the potential to improve health and spot signs of lung infections days before symptoms appear, avoiding admissions to hospital.
The team, led by Professor Andres Floto (Royal Papworth Hospital and the University of Cambridge), will examine the impact of home monitoring and machine-learning decision support algorithms for people with cystic fibrosis (CF) and non-CF bronchiectasis (NCFB).
The team has previously completed a multicentre UK-wide feasibility study (SmartCare CF) which demonstrated the potential benefits of home monitoring in CF. From that, the team ran a clinical implementation programme (Project Breathe), introducing home monitoring into routine clinical care in four CF centres in the UK and Ontario, Canada.
Research participants were provided with equipment – such as a FitBit, pulse oximeter, spirometer and electronic scales – to measure key indicators such as blood oxygen levels, lung function, weight, sleep and temperature every day, and then upload the results via a software platform (Breathe RM).
Data scientists from the University of Cambridge and Microsoft Research have now used this anonymised home monitoring data to train machine-learning algorithms to predict future health deteriorations 10 days earlier than currently possible. This would allow clinicians to begin treating patients sooner to potentially head off serious, lung damaging infections.
The researchers will receive £1.9m from medical research charity LifeArc and £1.5m from the National Institute for Health and Care Research to test the artificial intelligence technology at scale in a clinical trial.
They will explore the application of novel sensors to monitor health at home and to test the feasibility of home monitoring for patients with NCFB.
Starting in early 2023, the programme, which has been co-developed by people with direct experience of CF and NCFB, will enrol up to 500 adults with CF and NCFB across the UK.
The team will receive advice and support from LifeArc to develop the technology to commercial standard so it can be made available to patients worldwide.
If proven to be effective at scale, the technology could transform the lives of patients and deliver substantial cost and time savings for the NHS.
Professor Floto, Honorary Consultant at the Cambridge Centre for Lung Infection at Royal Papworth Hospital, said: “These studies are incredibly exciting. They have the potential to provide both immediate and long-term benefits to people living with chronic and debilitating lung conditions.
“It is a unique opportunity to empower people to take control of their own health and reduce the impact the disease has on their daily life, in turn improving their quality of care and saving time and money for the NHS.”
Dr Catherine Kettleborough, who leads the LifeArc Chronic Respiratory Infection Translational Challenge, said: “This new technology has the potential to transform how people living with chronic lung conditions like BE and CF monitor and manage their condition. By detecting infections before symptoms appear, this technology could enable patients to start treatment earlier before they become seriously unwell, avoiding unnecessary hospital admissions and massive disruption to their lives.”
“Self-monitoring my health through Project Breathe has helped me pick up signs of exacerbations more quickly, meaning problems have been intercepted earlier,” said Sammie Read, 42, from Stowmarket, Suffolk. “This has given me a better quality of life as I do not need to be admitted as an inpatient for intravenous antibiotics as often.”
Steve Churchill, 44 from Hertfordshire, also has CF and has been monitoring his health from home using technology since November 2019. “It was perfect timing for me with the COVID-19 pandemic arriving a few months later when I needed to shield. I have been able to keep an eye on my health more closely myself, a benefit that was particularly useful during the pandemic.
“There have been a few times when I have started oral antibiotics earlier than I would have done otherwise, which may have prevented some hospital stays because I’ve been able to spot a possible problem early.”
An additional arm of the trial will investigate the impact and effectiveness of novel, small wearable devices that continuously monitor the health of people with CF.
“It would be great to have the recording done passively,” added Steve. “Managing my CF takes a long time – four hours a day when I am well and far longer when I am ill. Anything that can reduce the burden of my health regime would be very welcome.”
“Having the data picked up more easily or automatically without having to record it myself would be even easier,” Sammie concluded. “It would save more time, allowing me to continue living my life without having to upload data daily.”